ASBPW · Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings has secured significant financing through a private placement of convertible preferred stock, raising $21 million in gross proceeds across two closings. The transaction structure includes favorable conversion terms for investors, with the conversion price set at a discount to market prices, potentially leading to dilution for existing shareholders. The company obtained necessary stockholder approval for conversion limits and has an effective registration statement for the underlying common shares, facilitating future conversions. Concurrently, the company amended its certificate of designation to clarify terms and increase the authorized share count, providing administrative flexibility. Management indicates the proceeds have bolstered the company's equity position above Nasdaq's minimum listing requirement, though formal confirmation from Nasdaq is pending. The offering involved conversion of existing debt and payment of placement agent fees, with the securities containing standard representations, warranties, and covenants for similar transactions.